Anzeige
Meldung des Tages: Mit Graphen gegen jede Abwehr — Die Zukunft der Drohnen ist da

Roche Holding News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
354,80 €
+5,60 €
+1,60%
30.04.26
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
10,22 EUR
Dividendenrendite
2,91%
Nachhaltigkeits-Score
60 %
Index-Zuordnung
-

Roche Holding News

30.04.26 - GlobeNewswire
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
New real-​world data confirm Vabysmo’s potent retinal drying in nAMD and DME Key data for Susvimo demonstrate its potential to provide lasting disease control through continuous ...
23.04.26 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
Group sales  were +6% at constant exchange rates (CER) 1 , -5% when reported in CHF and +9% in USD 2 , in the first three months, driven by high demand for our innovative ...
23.04.26 - GlobeNewswire
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens
Konzernverkäufe stiegen in den ersten drei Monaten um +6% zu konstanten Wechselkursen (CER 1 ; in CHF ausgewiesen -5% und auf USD-Basis 2 +9%) aufgrund hoher ...
22.04.26 - GlobeNewswire
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
Late-​breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in ...
21.04.26 - GlobeNewswire
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-​associated disease (MOGAD) MOGAD is a rare autoimmune ...
21.04.26 - GlobeNewswire
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus ...
13.04.26 - GlobeNewswire
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis. 1 This minimally ...
30.03.26 - GlobeNewswire
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs. The new test ...
23.03.26 - GlobeNewswire
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
The new building is part of a CHF 1.4 billion site investment, reinforcing Roche’s commitment to Switzerland and the Basel life sciences cluster The Institute of Human Biology (IHB) ...
23.03.26 - GlobeNewswire
Roche eröffnet neues Forschungsgebäude für das Institute of Human Biology und leistet damit Pionierarbeit im Bereich menschlicher Modellsysteme, um Entwicklung von Medikamenten zu beschleunigen
Das neue Gebäude ist Teil einer Investition in Höhe von CHF 1,4 Milliarden in den Standort und unterstreicht das Engagement von Roche in der Schweiz und für den Life Sciences ...
16.03.26 - GlobeNewswire
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-​cloud AI factory, totaling more than 3,500 GPUs. The ...
10.03.26 - GlobeNewswire
Roche Annual General Meeting 2026
Shareholders approved all proposals of the Board of Directors  Severin Schwan re-​elected as Chairman of the Board of Directors; all other Board members standing for election ...
10.03.26 - GlobeNewswire
Roche Generalversammlung 2026
Alle Anträge des Verwaltungsrates genehmigt Severin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und ...
09.03.26 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-​free survival, but a numerical improvement was observed  ...
07.03.26 - ARIVA.DE Redaktion
Schock für Anleger: Zealand-Aktie bricht ein – enttäuschende Studiendaten im Milliardenmarkt für Abnehmmedikamente
Mehr als 30 Prozent Kursverlust an nur einem Tag und 1,3 Milliarden US-Dollar Marktkapitalisierung futsch: Schwächere Studiendaten zum Adipositas-​Medikament Petrelintid ...
06.03.26 - GlobeNewswire
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-​point improvement in SRI-4, a measure that assesses disease severity and ...
05.03.26 - GlobeNewswire
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value At the maximally effective dose, there were no cases of vomiting and no ...
02.03.26 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), ...
20.02.26 - GlobeNewswire
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and  ESR1 -mutated ...
17.02.26 - IT-Times
Change to the Roche Enlarged Corporate Executive Committee

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »